Instrucciones de búsqueda:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Navegar por los elementos (92 total)
-
Autor: WHO
Tema: Infection Control
Tipo de elemento: Publicación
Fecha de actualización: 2019-04-12
Descripción: ABOUT THIS ANALYSIS: DRC’s national research institute, the Institut National pour la Recherche Biomedicale (INRB) and WHO have conducted a preliminary analysis of the data being collected from the ring vaccination protocol. The analysis summarized… -
Autor: Ward, Brian J., Alexander Makarkov, Annie Séguin, Stéphane Pillet, Sonia Trépanier, Jiwanjeet Dhaliwall, Michael D. Libman, Timo Vesikari, and Nathalie Landry.
Tema: Laboratory
Tipo de elemento: Publicación
Fecha de actualización: 2020-10-13
Descripción: Seasonal influenza remains a substantial public health threat despite the availability of egg-derived and other vaccines. Plant-based manufacturing might address some of the limitations of current vaccines. We describe two phase 3 efficacy studies of… -
Autor: Walsh, Edward E., Robert W. Frenck, Ann R. Falsey, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kathleen Neuzil, Mark J. Mulligan, Ruth Bailey, Kena A. Swanson, Ping Li, Kenneth Koury, Warren Kalina, David Cooper, Camila…
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-10-14
Descripción: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is… -
Autor: Varkey, J. B. and B. S. Ribner
Tema: General
Tipo de elemento: Publicación
Fecha de actualización: 2016-06-01
Descripción: Ending the West Africa Ebola virus disease (EVD) outbreak required an unprecedented international response. -
Autor: University of Minnesota, Center for Infectious Disease Research and Policy
Tema: Treatment & Care
Tipo de elemento: Publicación
Fecha de actualización: 2017-01-17
Descripción: In the third major report from the Wellcome Trust–CIDRAP Ebola Vaccine Team B reflects on progress to date and the remaining challenges faced. -
Autor: United Kingdom Department of Health (DH)
Tema: Research
Tipo de elemento: Guía
Fecha de actualización: 2019-07-19
Descripción: This report summarizes the establishment of the Ebola Biobank, its governance, and how materials were safely transported in 2015 from West Africa to the United Kingdom for curation by Public Health England. The Biobank is a secure but accessible… -
Autor: the Oxford COVID-19 Vaccine Trial Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-03-30
Descripción: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this variant. -
Autor: the Oxford COVID Vaccine Trial Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-02-19
Descripción: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. -
Autor: the Oxford COVID Vaccine Trial Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2020-12-08
Descripción: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19… -
Autor: the mRNA-1273 Study Group
Tema: Research
Tipo de elemento: Publicación
Fecha de actualización: 2021-04-06
Descripción: Interim results from a phase 3 trial of the Moderna mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine indicated 94% efficacy in preventing coronavirus disease 2019 (Covid-19).